Incyte announces data from Phase 2b study evaluating Povorcitinib

Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented in a late-breaking oral presentation at the 2023 American Academy of Dermatology Annual Meeting, held from March 17-21 in New Orleans. Results from the study demonstrate that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index scores. Specifically, the study met its primary endpoint and patients receiving povorcitinib experienced statistically superior improvements in T-VASI at Week 24 compared to placebo. Additionally, more patients who received povorcitinib achieved the key secondary endpoint of T-VASI50 at Week 24 and continued to improve during an open-label extension period through Week 36 of treatment, following dose adjustment.